Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy
Inovio to Present at Upcoming Investor Conferences
AstraZeneca Unit to Buy Definiens
AstraZeneca Unit to Buy Privately-Held Definiens For $150 Million
Inovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014
AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors
Week ending April 27: Quarterly earnings continue to boost market's spirits.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...